{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:37:50Z","timestamp":1790793470851,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clineuro.2021.106563","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:42:31Z","timestamp":1613436151000},"page":"106563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?"],"prefix":"10.1016","volume":"203","author":[{"given":"Abdorreza","family":"Naser Moghadasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shabany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hora","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharareh","family":"Eskandarieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clineuro.2021.106563_bib0005","series-title":"\u2018Pneumonia of Unknown Cause \u2013 China\u2019, Emergencies Preparedness, Response, Disease Outbreak News","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.clineuro.2021.106563_bib0010","series-title":"The SARS, MERS and Novel Coronavirus (COVID-19) Epidemics, the Newest and Biggest Global Health Threats: What Lessons Have We Learned?","author":"Peeri","year":"2020"},{"key":"10.1016\/j.clineuro.2021.106563_bib0015","series-title":"Rolling Updates on a Coronavirus Disease (COVID-19)","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.clineuro.2021.106563_bib0020","series-title":"Coronavirus","author":"Worldmeter","year":"2020"},{"key":"10.1016\/j.clineuro.2021.106563_bib0025","series-title":"Association of British Neurologists Guidance on COVID-19 for People With Neurological Conditions, Their Doctors and Carers","author":"ABN - Association of British Neurologists","year":"2020"},{"key":"10.1016\/j.clineuro.2021.106563_bib0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/7651_2014_151","article-title":"Neuropathological techniques to investigate central nervous system sections in multiple sclerosis","volume":"1304","author":"Bauer","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.clineuro.2021.106563_bib0035","doi-asserted-by":"crossref","first-page":"102358","DOI":"10.1016\/j.msard.2020.102358","article-title":"Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument","volume":"44","author":"Ahmad","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.clineuro.2021.106563_bib0040","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2021.106563_bib0045","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13760-017-0772-0","article-title":"Corticosteroids in the management of acute multiple sclerosis exacerbations","volume":"117","author":"Smets","year":"2017","journal-title":"Acta Neurol. Belg."},{"issue":"5","key":"10.1016\/j.clineuro.2021.106563_bib0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ejhpharm-2018-001499","article-title":"High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient\u2019s satisfaction","volume":"26","author":"Horta-Hern\u00e1ndez","year":"2019","journal-title":"Eur. J. Hosp. Pharm. Sci. Pract."},{"issue":"6","key":"10.1016\/j.clineuro.2021.106563_bib0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s004150070172","article-title":"Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials","volume":"247","author":"Brusaferri","year":"2000","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106563_bib0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2826.2011.02161.x","article-title":"Mechanisms of glucocorticoids in the control of neuroinflammation","volume":"24","author":"Schweingruber","year":"2012","journal-title":"J. Neuroendocrinol."},{"issue":"11","key":"10.1016\/j.clineuro.2021.106563_bib0065","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1177\/1352458516681198","article-title":"Infection-related health care utilization among people with and without multiple sclerosis","volume":"23","author":"Wijnands","year":"2017","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.clineuro.2021.106563_bib0070","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/1352458519872664","article-title":"Environmental factors and risk of multiple sclerosis: findings from meta-analyses and Mendelian randomization studies","volume":"26","author":"Belbasis","year":"2020","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.clineuro.2021.106563_bib0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2008.07.010","article-title":"Use of glucocorticoids and risk of infections","volume":"8","author":"Cutolo","year":"2008","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.clineuro.2021.106563_bib0080","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41582-019-0194-0","article-title":"Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis","volume":"15","author":"Zipp","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.clineuro.2021.106563_bib0085","doi-asserted-by":"crossref","first-page":"102182","DOI":"10.1016\/j.msard.2020.102182","article-title":"A fine balance: immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19","author":"Valencia-Sanchez","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2021.106563_bib0090","doi-asserted-by":"crossref","first-page":"105955","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","author":"Zhai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.clineuro.2021.106563_bib0095","first-page":"42","article-title":"The big challenge for neurologists in treating patients with multiple sclerosis in the post-COVID-19 era","author":"Moghadasi","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.clineuro.2021.106563_bib0100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2021.106563_bib0105","doi-asserted-by":"crossref","first-page":"e103409","DOI":"10.5812\/ans.103409","article-title":"Should Patients with MS Discontinue Their Medications During the COVID-19 Pandemic?","volume":"7","author":"Naser Moghadasi","year":"2020","journal-title":"Arch. Neurosci."},{"issue":"3","key":"10.1016\/j.clineuro.2021.106563_bib0110","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/CON.0000000000000739","article-title":"Management of multiple sclerosis relapses","volume":"25","author":"Repovic","year":"2019","journal-title":"Contin. Lifelong Learn. Neurol."},{"issue":"11","key":"10.1016\/j.clineuro.2021.106563_bib0115","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1177\/0961203318792352","article-title":"Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort","volume":"27","author":"Yang","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.clineuro.2021.106563_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2020.04.006","article-title":"Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan","author":"Li","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106563_bib0125","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.jinf.2020.04.008","article-title":"Risk factors associated with disease severity and length of hospital stay in COVID-19 patients","volume":"81","author":"Liu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.clineuro.2021.106563_bib0130","article-title":"Dexamethasone in hospitalized patients with Covid-19\u2014preliminary report","author":"Group","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 1","key":"10.1016\/j.clineuro.2021.106563_bib0135","first-page":"S5","article-title":"Consensus statement on immune modulation in multiple sclerosis and related disorders during the covid-19 pandemic: expert group on behalf of the indian academy of neurology","volume":"23","author":"Bhatia","year":"2020","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.clineuro.2021.106563_bib0140","doi-asserted-by":"crossref","first-page":"102472","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2021.106563_bib0145","first-page":"42","article-title":"Rethinking high-risk groups in COVID-19","author":"Vishnevetsky","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clineuro.2021.106563_bib0150","first-page":"42","article-title":"Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): a report from Iran","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.clineuro.2021.106563_bib0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol. Cell. Endocrinol."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846721000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:35:18Z","timestamp":1759588518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846721000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":31,"alternative-id":["S0303846721000901"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106563","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2021.106563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106563"}}